Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...
Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
Abbott ($ABT) now has a mobile app to collect and share data for its continuous glucose monitor that doesn't require routine finger-stick calibration, FreeStyle Libre ...
SAN FRANCISCO--(BUSINESS WIRE)--Today, Nutrino, (www.nutrino.co) announces the collaboration with the LibreLink 1, 2 application, designed for Abbott’s FreeStyle Libre Flash Glucose Monitoring system.
AbbottABT announced the availability of FreeStyle LibreLink app in Europe for use in smartphones(both iPhone and Android). Notably, diabetes patients using the ...
The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...
Please provide your email address to receive an email when new articles are posted on . Abbott and Sanofi on Monday announced a partnership to develop new tools that will combine technology from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback